Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?

Breast J. 2018 Jul;24(4):459-461. doi: 10.1111/tbj.12932.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Breast Neoplasms*
  • Carboplatin
  • Colony-Stimulating Factors
  • Docetaxel
  • Humans
  • Neoadjuvant Therapy
  • Receptor, ErbB-2
  • Trastuzumab*

Substances

  • Colony-Stimulating Factors
  • Docetaxel
  • Carboplatin
  • Receptor, ErbB-2
  • Trastuzumab